AKT1 and cancer: While Loureirin A and Loureirin B show potential in modulating multiple signaling pathways involved in cancer progression, including the MAPK, PI3K/AKT, and Wnt/β-catenin pathways, compounds that affect multiple pathways are often metabolized rapidly.